HANSOH PHARMA (03692): HS-20152 injection fluid has been issued with a drug clinical trial approval notice by the National Medical Products Administration.
Hansom Pharmaceuticals (03692) announced that the Group's independently developed new drug HS-20152 injection has received a drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) of China, and is intended to conduct clinical trials for paroxysmal nocturnal hemoglobinuria.
Hansoh Pharma (03692) announced that the Group's independently developed new drug HS-20152 injection has obtained the drug clinical trial approval notification issued by the China National Medical Products Administration (NMPA), and it plans to conduct clinical trials for paroxysmal nocturnal hemoglobinuria.
Related Articles
Historic moment! The first successful implementation of BNCT treatment in Hainan CH Biotech Co., Ltd. (08037) is revalued and industry breakthroughs.
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Historic moment! The first successful implementation of BNCT treatment in Hainan CH Biotech Co., Ltd. (08037) is revalued and industry breakthroughs.
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
